IST	Genetic
CON	Property Rights
REL	on
CON	Trial
GPE	LONDON
NIL	–
REL	In
IST	early
MOY	February
MOY	2010
EQU	,
DIS	a
CON	United States
IST	federal
CON	district
CON	court
REL	in
GEO	New York
EPS	began
EXS	deciding
DIS	a
CON	landmark
CON	case
AND	as
SUB	to
SUB	whether
CON	individuals
NOW	have
DIS	a
CON	“right
SUB	to
EXS	know
NIL	”
AND	about
QUE	how
HAS	their
IST	own
CON	genomes
POS	can
CON	dictate
HAS	their
CON	future
CON	health
NIL	.
DEF	The
CON	case
NIL	,
GPO	American
ORG	Civil
ORG	Liberties
ORG	Union
REL	v.
PER	Myriad
ORG	Genetics
NIL	,
POS	may
EXS	have
DIS	a
IST	tremendous
CON	impact
REL	on
CON	medicine
AND	and
CON	science
NIL	.
DEF	The
CON	questions
REL	on
UNK	which
DEF	the
CON	case
CON	turns
NOW	are
SUB	whether
IST	genetic
CON	patents
EXS	help
DIS	or
EXS	hamper
CON	research
NIL	,
COO	and
SUB	whether
CON	patients
NEC	should
EXS	have
SUB	to
EXS	pay
DIS	a
CON	license
CON	fee
REL	to
DIS	a
CON	biotechnology
CON	corporation
SUB	to
EXS	be
EXS	tested
REL	for
CON	predisposition
REL	to
CON	disease
NIL	.
QUC	One
AND	of
DEF	the
CON	plaintiffs
NOW	is
PER	Lisbeth
PER	Ceriani
EQU	,
DIS	a
IST	43-year-old
CON	woman
REL	with
CON	breast
CON	cancer
HAS	whose
CON	doctors
PST	recommended
SUB	that
PRO	she
EXS	be
EXS	tested
REL	for
QUC	two
IST	genetic
CON	mutations
EXS	involved
REL	in
DIS	some
IST	hereditary
CON	forms
AND	of
DEF	the
CON	disease
NIL	.
ORG	Myriad
ORG	Genetics
EQU	,
DEF	the
XCL	sole
CON	test
CON	provider
REL	in
DEF	the
ORG	US
NIL	–
PRO	it
NOW	holds
DIS	a
CON	patent
REL	on
DEF	the
CON	genes
REF	themselves
NIL	,
NOT	not
AND	just
REL	on
DEF	the
IST	diagnostic
CON	test
NIL	–
PST	did
NOT	not
EXS	accept
HAS	her
CON	insurance
NIL	,
COO	and
GPO	Ceriani
POS	could
NOT	not
EXS	afford
SUB	to
EXS	pay
REL	for
DEF	the
CON	test
NIL	.
AND	So
PRO	she
EPS	remained
EXS	ignorant
NIL	,
AND	as
PST	did
HAS	her
CON	physicians
NIL	–
REL	with
IST	possible
CON	ramifications
REL	for
HAS	her
IST	clinical
CON	care
NIL	.
QUC	Five
ALT	other
CON	plaintiffs
NIL	–
AND	along
REL	with
IST	major
IST	medical
CON	bodies
NOW	–
EXS	tell
IST	similar
CON	stories
NIL	.
DST	Those
AND	who
NOW	oppose
IST	genetic
CON	patents
ENS	claim
SUB	that
PRO	they
IST	also
EXS	deny
ORG	US
IST	constitutional
CON	rights
NIL	,
EXS	making
PRX	this
DEF	the
IST	first
CON	time
DIS	a
IST	genetic
CON	patent
NOW	has
PFT	been
EPS	challenged
REL	on
IST	human
CON	rights
CON	grounds
NIL	.
AND	As
AND	so
IST	often
ENS	happens
REL	in
CON	biotechnology
NIL	,
QUE	what
NOW	looks
REL	at
IST	first
AND	like
DIS	an
IST	abstruse
IST	technical
CON	issue
NOW	raises
QUV	many
CON	questions
SUB	that
EXS	cut
SUB	to
DEF	the
CON	core
AND	of
HAS	our
CON	humanity
NIL	.
QUC	One
IST	human
CON	gene
AND	out
AND	of
APX	approximately
AND	every
QUC	five
NOW	is
NOW	now
DEF	the
CON	subject
AND	of
DIS	a
CON	patent
NIL	,
DEF	the
CON	majority
AND	of
UNK	which
NOW	are
EXS	held
REL	by
IST	private
CON	firms
NIL	.
PRX	This
CON	case
NOW	concerns
QUC	two
AND	such
CON	genes
EQU	,
UNK	BRCA1
EQU	and
UNK	BRCA2
NIL	.
CON	Women
REL	with
DEF	the
IST	“
CON	wrong
NIL	”
CON	version
AND	of
PRX	these
CON	genes
NOW	have
DIS	a
IST	heightened
CON	risk
AND	of
EXG	developing
CON	breast
CON	cancer
SUB	(
IST	up
REL	to
QUC	85
UOM	%
NIL	,
AND	against
DEF	the
IST	normal
QUC	12
UOM	%
NIL	,
SUB	although
DEF	the
CON	genes
CON	account
REL	for
XCL	only
DIS	a
CON	minority
AND	of
CON	breast
CON	cancers
NIL	)
NIL	.
PRX	These
CON	women
ALT	also
EXS	run
DIS	a
MOR	greater
CON	risk
AND	of
IST	ovarian
CON	cancer
NIL	.
ORG	Myriad
ORG	Genetics
NIL	also
NOW	has
EPS	tried
SUB	to
EXS	pursue
CON	patent
CON	rights
REL	in
GEO	Europe
NIL	,
COO	but
UNK	there
HAS	its
CON	claims
NOW	have
PFT	been
IST	largely
EXS	rejected
NIL	.
SUB	Although
DEF	the
CON	gene
AND	’s
CON	function
REL	in
EXG	causing
CON	breast
AND	and
IST	ovarian
CON	cancer
PST	was
EXS	uncovered
REL	by
REL	Cancer
ORG	Research
ORG	UK
REL	in
YOC	1995
NIL	,
GEO	Myriad
NIL	,
AND	along
REL	with
INT	nearly
QUC	30
ALT	other
CON	defendants
NIL	,
NOW	argues
SUB	that
DEF	the
CON	patent
NOW	is
DIS	a
IST	necessary
CON	reward
REL	for
HAS	its
CON	research
CON	costs
NIL	.
